New platform aims to personalize cancer treatment for GI patients
NCT ID NCT04724070
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to create a comprehensive precision oncology platform at the Chinese University of Hong Kong to personalize drug therapy for 170 patients with advanced gastrointestinal cancers. Researchers will collect tumor samples for genetic sequencing and grow patient-derived cancer models to test drugs. The goal is to improve treatment matching and build a biobank for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could create a personalized drug screening system to better match treatments to individual patients with advanced gastrointestinal cancers.
What could go wrong
This is an observational platform study, not a treatment trial. It focuses on building tools and collecting data, so direct patient benefits are not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Chinese University of Hong Kong
Hong Kong, Hong Kong